Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Saga University currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. This distribution indicates that the university's patent applications are being reviewed independently by different individuals in separate administrative divisions. The presence of 3 distinct examiners for 3 pending actions indicates that each application is being evaluated by a different reviewer.
HOLLY MICHAELA KIPOUROS is the busiest examiner for the portfolio, handling 1 pending office action. With 3 pending office actions total and a busiest examiner pending count of 1, the workload is distributed among the 3 distinct examiners. This lack of concentration means that prosecution outcomes are not dependent on a single examiner's review. Practitioners should prepare to navigate the individual requirements of 3 different reviewers across 3 art units within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIPOUROS, HOLLY MICHAELA | 1 | 69.5% | +21.6% |
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
| KELLY-O'NEILL, YOLANDA LYNNETTE | 1 | 33.3% | +29.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | CRAIGO, BAHAR ALAWI | 23d |
| 18578809 | CULTURE SYSTEM | KIPOUROS, HOLLY MICHAELA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | CRAIGO, BAHAR ALAWI | 23d |
| 18578809 | CULTURE SYSTEM | KIPOUROS, HOLLY MICHAELA | — |
| 18210750 | METHOD FOR PRODUCING FLUORINATED ORGANIC COMPOUND | KELLY-O'NEILL, YOLANDA LYNNETTE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1699 | 1 |
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578809 | CULTURE SYSTEM | KIPOUROS, HOLLY MICHAELA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18271829 | INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS | CRAIGO, BAHAR ALAWI | 1699 | §102§103§112 | Non-Final OA | 23d | Pending | Jul 11, 2023 |
| 18210750 | METHOD FOR PRODUCING FLUORINATED ORGANIC COMPOUND | KELLY-O'NEILL, YOLANDA LYNNETTE | 1692 | §103 | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial